Thus, while further research is warranted to fully elucidate the long-term benefits of SGLT2 inhibitors in HFpEF populations, current evidence supports their role as a key component in the evolving treatment landscape for HF [4,63,69]. Here, SLC5A2 is linked to hydrops fetalis.